PATENT CLAIM ANALYSIS

Application Number: 16308908
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non-purine selective inhibitor of xanthine oxidase, in particular Febuxostat and an effective amount of an alkalizing agent. It also relates to a process for the preparation thereof.

Claim (Index 7):
The pharmaceutical composition according to  claim 1 , wherein it further comprises at least one pharmaceutical acceptable excipient selected from diluents, binders, disintegrants and lubricants.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 98.0
- Lexical Diversity: 1.325
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13160572', '15010212', '12739475', '14006032', '13990632']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7228566336634005
- 35 USC 102 Novelty (BERT): 0.4722791106581883
- Combined Prediction Score: 0.6977988813628793
- Mean Citation Score: 167.35468000000003
- Max Citation Score: 190.09056
- Similarity Product: 154.59102428398134

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test